Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

TAK-330

Phase 3Small molecule

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Factor Xa InhibitorRecruiting

Factor Xa InhibitorPhase 3

Recruiting

Timeline

Expected Milestones

Q2 2028

Phase 3Recruiting

Factor Xa Inhibitor

NCT05156983

Clinical

Trials by Indication[1]

Factor Xa Inhibitor1 trial

A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery

Recruiting· Takeda logo

Takeda·Phase 3·NCT05156983·328 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TAK-330. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TAK-330 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TAK-330. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Takeda

Related News